1,3-dipropyl-8-(2-amino-4-chlorophenyl)xanthine has been researched along with dinoprostone in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chabardès, D; Montégut, M; Siaume-Perez, S; Zhou, Y | 1 |
| Aley, KO; Green, PG; Levine, JD | 1 |
| Aley, KO; Levine, JD | 1 |
3 other study(ies) available for 1,3-dipropyl-8-(2-amino-4-chlorophenyl)xanthine and dinoprostone
| Article | Year |
|---|---|
Two mechanisms of inhibition by prostaglandin E2 of hormone-dependent cell cAMP in the rat collecting tubule.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Adenosine; Animals; Arginine Vasopressin; Colforsin; Cyclic AMP; Dinoprostone; Indomethacin; Isoproterenol; Kidney Tubules, Collecting; Male; Phenylisopropyladenosine; Rats; Rats, Inbred Strains; Signal Transduction; Xanthines | 1990 |
Opioid and adenosine peripheral antinociception are subject to tolerance and withdrawal.
Topics: Adenosine; Analgesics; Animals; Dinoprostone; Drug Tolerance; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalins; Hyperalgesia; Male; Morphine; Naloxone; Narcotic Antagonists; Narcotics; Nociceptors; Rats; Rats, Sprague-Dawley; Xanthines | 1995 |
Multiple receptors involved in peripheral alpha 2, mu, and A1 antinociception, tolerance, and withdrawal.
Topics: Adenosine; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Analgesics; Analgesics, Opioid; Animals; Clonidine; Dinoprostone; Drug Interactions; Drug Tolerance; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalins; Hyperalgesia; Male; Models, Biological; Naloxone; Narcotic Antagonists; Oligonucleotides, Antisense; Purinergic P1 Receptor Agonists; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Receptors, Opioid, mu; Receptors, Purinergic P1; Second Messenger Systems; Substance Withdrawal Syndrome; Substance-Related Disorders; Xanthines; Yohimbine | 1997 |